JOJill Isabelle Olydam

Jill Isabelle Olydam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jill Isabelle Olydam has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis

    by J. I. Olydam, S. Sengkerij, S. Veenbergen, D. J. Hijnen

    Summary: Serum eosinophil‐derived neurotoxin levels correlate with eosinophil activation and disease activity in atopic dermatitis. Reduced serum eosinophil‐derived neurotoxin levels after cyclosporine therapy indicate treatment response and efficacy monitoring potential.

  • Open Access

    Serum proteomic changes in atopic dermatitis patients treated with cyclosporine

    by Jill Isabelle Olydam, Thomas Litman, Tamar Nijsten, Ilka Hoof, Witte Koopmann, Luba Milena Pardo, DirkJan Hijnen

    Background: Despite significant advancements in atopic dermatitis (AD) treatment, the underlying pathogenesis remains unclear. Understanding flare and remission mechanisms is essential for understanding disease course, evaluating treatment and developing therapeutic strategies. Although biomarkers show promise for assessing disease severity, their identification, validation and clinical utility demand further research. Objectives: To investigate inflammatory changes involved in AD flares and remissions, we studied changes in expression of 368 circulating biomarkers during cyclosporine (CsA) treatment. Methods: The study included 40 AD patients experiencing a disease flare and starting CsA treatment. Serum samples were collected at baseline, after 2 and 4 weeks of treatment. Results: CsA treatment induced a rapid improvement of disease severity and reduced proteins related to Th2, Th1 and Th17 pathways. Four novel markers, FKBP1B, PDLIM7, MAP2K6 and EIF4G1 demonstrated decreased expression levels after treatment. In addition, CCL17/TARC and OX40 levels showed a strong correlation with disease severity. Interestingly, NME3, SMOC2, and GAL showed increased expression after treatment. We identified four biomarkers that may be linked to the pathogenesis of flares and remissions. Lastly, we identified OX40 as a potential biomarker for disease severity. Conclusion: We identified four novel serum biomarkers possibly related to treatment effect and we identified OX40 as a potential serum biomarker for assessing disease severity. These findings enhance understanding of AD pathogenesis and offer tools for monitoring therapeutic response and disease severity.


  • Open Access

    Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort

    by Anne R. Schlösser, Neill Boeijink, Jill Olydam, Tamar E. C. Nijsten, DirkJan Hijnen

    Background: Upadacitinib was the first JAK‐1 selective inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real‐world data on the use of upadacitinib in patients that have been treated with other immunosuppressants and targeted therapies is limited.Objectives: To provide real‐world evidence on the use of upadacitinib treatment in moderate‐to‐severe atopic dermatitis.Methods: In this prospective observational single‐centre study, all AD patients treated with upadacitinib treatment in the context of standard care were included between August 2021 and September 2022. Clinical outcome measures and adverse events (AEs) were analysed.Results: Forty‐eight patients were included. The majority (n = 39; 81%) had failed (ineffectiveness) on other targeted therapies, including other JAK inhibitors and biologics. Thirty‐four (71%) patients were still using upadacitinib treatment at last follow up (median duration 46.5 weeks). Fourteen (29%) patients discontinued treatment due to ineffectiveness or AE. Upadacitinib treatment led to a significant decrease of disease severity during a median follow up of 37.5 weeks. Median IGA at baseline decreased from 3 (IQR 2–3) to 1.5 (IQR 1–2) at last review (p < 0.001). Median NRS itch decreased from 7 (IQR 5–8) at baseline to 2.25 (IQR 0.25–6.5) at last review (p < 0.001). Three patients discontinued treatment due to AE. Forty‐eight AEs were reported, including acne‐like eruptions (25%), nausea (13%) and respiratory tract infections (10%).Conclusions: In this real‐world cohort, we confirmed that upadacitinib is an effective treatment in a subset of AD patients that have failed several previous systemic immunosuppressive and biologic treatments. Overall, AE were mostly well tolerated and not a reason to discontinue treatment for most patients.


  • Open Access

    Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis

    by J. I. Olydam, A. R. Schlösser, P. Custurone, T. E. C. Nijsten, D. Hijnen

    Background: Abrocitinib is a JAK‐1 selective inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown in phase 3 clinical trials, data on real‐world patients with a treatment history of advanced systemics are scarce.Objectives: The objective of the study was to evaluate the effectiveness and safety of abrocitinib treatment in patients with difficult‐to‐treat AD in daily practice.Methods: In this prospective observational single‐centre study, all AD patients who started abrocitinib treatment in the context of standard care between April 2021 and December 2022 were included. Effectiveness was assessed using clinician‐ and patient‐reported outcome measures. Adverse events were evaluated.Results: Forty‐one patients were included. The majority (n = 30; 73.2%) had failed (ineffectiveness) on other targeted therapies, including JAK inhibitors (n = 14, 34%) and biologics (n = 16, 39%). Abrocitinib treatment resulted in a significant decrease in disease severity during a median follow‐up period of 25 weeks (IQR 16–34). Median EASI score at baseline decreased from 14.7 (IQR 10.4–25.4) to 4.0 (IQR 1.6–11.4) at last review (p < 0.001). Median NRS itch decreased from 7.0 (IQR 5–8) to 3.0 (IQR 1–2) at last review (p < 0.001). The most frequently reported AEs included gastrointestinal symptoms (27.6%), acne (20.7%) and respiratory tract infections (17.2%). 16 (39%) patients discontinued abrocitinib treatment due to ineffectiveness, AEs or both (41.2%, 41.2% and 11.8%, respectively).Conclusion: Abrocitinib can be an effective treatment for patients with moderate‐to‐severe AD in daily practice, including non‐responders to other targeted therapies.


  • Prediction of response to dupilumab treatment

    by DirkJan Hijnen, Jill Olydam

    One of the holy grails of modern medicine is choosing the right drug for the right patient. In this issue of the BJD, Wu et al. present their search for predictive serum biomarkers in patients with atopic dermatitis (AD) treated with dupilumab.1 Treatment options for moderate-to-severe AD have evolved since registration of the first biologic, dupilumab, in 2017. Currently, there are two biologics and three Janus kinase inhibitors registered for the treatment of moderate-to-severe AD. Although this new armamentarium fills a high unmet need, success in choosing the right drug for the right patient remains elusive. Currently, treatment decisions in patients eligible for advanced systemics are largely based on expert opinion and patient preferences, such as preferred route of administration (e.g. oral vs. subcutaneous). This often results in a trial-and-error approach and unnecessary exposure of patients to drugs that are not effective, and may result in side-effects. In addition, it leads to inefficient use of expensive drugs in an era of exponentially increasing healthcare expenses. Predictive biomarkers have the potential to optimize treatment response, minimize side-effects and ultimately reduce healthcare costs.

  • Open Access

    Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice

    by Anne R Schlösser, Madena Shareef, Jill Olydam, Tamar E C Nijsten, Dirk Jan Hijnen

    Background: Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. Aim: To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD. Methods: In this observational prospective study, patients with AD who received tralokinumab treatment in the context of routine care at the Erasmus Medical Centre were included between November 2021 and February 2022. This included 28 patients who had previously been treated with dupilumab, and 14 patients who had been treated with a Janus kinase inhibitor (JAKi). The Investigator’s Global Assessment (IGA; 0–4) and the numeric rating scale peak pruritus during the past 7 days (NRS itch 7d: 0–10), adverse events and reasons for discontinuation were analysed. A good clinical response was defined as any decrease in IGA and NRS itch 7d and if a patient was satisfied with the treatment and wished to continue with therapy. Results: In total, 37 patients were treated with tralokinumab. Twenty-two (59%) patients showed a good response to tralokinumab treatment. Fifteen (41%) patients discontinued treatment because of inadequate AD control or adverse events. Treatment-related adverse events were mild in most patients. Half of the patients where treatment with dupilumab had failed had a good clinical response to tralokinumab. Conclusions: Tralokinumab was found to be effective in most patients in this cohort with difficult-to-treat, severe AD from daily practice. Interestingly, tralokinumab was also found to be effective in 50% of patients who had previously experienced insufficient response or adverse events with dupilumab treatment.


  • Open Access

    Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences

    by Jill I. Olydam, Linde E. M. de Wijs, Tamar E. C. Nijsten, Joost van Rosmalen, Dirk Jan Hijnen

    Background: Clinical trials with dupilumab in atopic dermatitis (AD) patients showed a trend towards better effectiveness with a weekly or biweekly dosing interval, compared with extended dosing intervals. However, literature about adjusted dose regimens in daily practice is lacking.Objectives: To evaluate adjusted dosing intervals of dupilumab for AD in daily practice.Methods: An observational, longitudinal cohort study was conducted in AD patients who started dupilumab treatment in daily practice. Dosing intervals were adjusted upon shared decision making between physicians and patients in daily practice, without strict criteria. Disease courses of patients with shortened or extended dosing intervals were illustrated using spaghetti plots. In addition, data of patients who were treated with standard or extended dosing intervals were analysed using linear mixed effect (LME) models to determine the estimated effectiveness of extended dosing regimens.Results: In total, 180 AD consecutive patients treated with dupilumab in daily practice were included in our study. Patients with an extended dosing interval (n = 28) had relatively low Eczema Area and Severity Index (EASI) scores at the time of interval adjustment (range: 0−7) and the majority of patients showed continuous effectiveness after adjustment. In patients with a shortened dosing interval (n = 26), the scores at the time of adjustment were more widespread (range: 0−34) and follow‐up showed variable disease courses. Based on the LME model, we found an overall continuous improvement of EASI scores in time, in patients with a regular and extended interval.Conclusions: Patients with extended dosing intervals showed sustained effectiveness, similar to patients with standard dosing intervals. The effects of shortened intervals on disease severity could not be adequately analysed due to methodological limitations in this retrospective study.


  • Open Access

    EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab

    by Jill I. Olydam, Linde E.M. de Wijs, Willem A. Dik, Mads A. Røpke, Joel Correa Da Rosa, Dirk Jan Hijnen


  • Open Access

    COVID‐19 in patients with cutaneous immune‐mediated diseases in The Netherlands: real‐world observational data

    by L.E.M. de Wijs, M.M. Joustra, J.I. Olydam, T. Nijsten, D.J. Hijnen

    Literature about COVID‐19 infections in patients with chronic inflammatory (skin) diseases treated with or without systemic therapy is scarce and controversial.1‐6 Therefore, we aimed to investigate the incidence and clinical course of COVID‐19 related symptoms and the effect on clinical and psychological symptoms in patients with atopic dermatitis (AD) and psoriasis vulgaris (PsO).